Urology dpt, First Affiliated Hospital of Nanjing Medical University
Urology dpt, First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, metastatic prostate carcinoma, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 3 | 2023-12-26 | NCT06177015 | |
| Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, metastatic prostate carcinoma, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 3 | 2023-08-09 | NCT05983783 | |
| Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Recruiting | Phase 3 | 2023-07-21 | NCT05956639 |